Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling in carmustine-resistant melanoma A2058 cells

ABSTRACT: Analysis of gene expression and compare the significant changed genes with associated phenotypes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE135689 | GEO | 2020/08/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profiling in cancer stem-like melanoma A2058 cells under normoxia and hypoxia

Project description:Analysis of gene expression and compare the significant changed genes with associated phenotypes

2024-01-31 | GSE166031 | GEO

Gene expression profiling in anchorage-independent melanoma A375 cells

Project description:Analysis of gene expression and compare the significant changed genes with associated phenotypes

2012-12-13 | GSE42876 | GEO

Gene expression profiling in 3 different melanoma cells under adhesion and suspension

Project description:Analysis of gene expression and compare the significant changed genes with associated phenotypes

2022-08-02 | GSE198509 | GEO

Gene expression profiling in melanoma A375 cells under anchorage, suspension, and reattachment from suspension

Project description:Analysis of gene expression and compare the significant changed genes with associated phenotypes

2014-09-24 | GSE61671 | GEO

Gene expression profiling in anchorage-independent melanoma A375 cells

Project description:Analysis of gene expression and compare the significant changed genes with associated phenotypes Total RNA extracted from adherent and suspension culture of A375 cells

2012-12-13 | E-GEOD-42876 | biostudies-arrayexpress

Gene expression profiling in melanoma A375 cells under anchorage, suspension, and reattachment from suspension

Project description:Analysis of gene expression and compare the significant changed genes with associated phenotypes Total RNA extracted from adherent, and suspended, and reattached A375 cells

2014-09-24 | E-GEOD-61671 | biostudies-arrayexpress

Gene expression profiling in carmustine-resistant melanoma A2058 cells

Project description:Gene expression profiling in carmustine-resistant melanoma A2058 cells

| PRJNA559721 | ENA

CRISPR/Cas9 Mediated Knockout of Cyclooxygenase-2 Gene Inhibits Invasiveness in A2058 Melanoma Cells.

Project description:The inducible isoenzyme cyclooxygenase-2 (COX-2) is an important hub in cellular signaling, which contributes to tumor progression by modulating and enhancing a pro-inflammatory tumor microenvironment, tumor growth, apoptosis resistance, angiogenesis and metastasis. In order to understand the role of COX-2 expression in melanoma, we investigated the functional knockout effect of COX-2 in A2058 human melanoma cells. COX-2 knockout was validated by Western blot and flow cytometry analysis. When comparing COX-2 knockout cells to controls, we observed significantly reduced invasion, colony and spheroid formation potential in cell monolayers and three-dimensional models in vitro, and significantly reduced tumor development in xenograft mouse models in vivo. Moreover, COX-2 knockout alters the metabolic activity of cells under normoxia and experimental hypoxia as demonstrated by using the radiotracers [18F]FDG and [18F]FMISO. Finally, a pilot protein array analysis in COX-2 knockout cells verified significantly altered downstream signaling pathways that can be linked to cellular and molecular mechanisms of cancer metastasis closely related to the enzyme. Given the complexity of the signaling pathways and the multifaceted role of COX-2, targeted suppression of COX-2 in melanoma cells, in combination with modulation of related signaling pathways, appears to be a promising therapeutic approach.

| S-EPMC8870212 | biostudies-literature

The Synergistic Activity of Bortezomib and TIC10 against A2058 Melanoma Cells.

Project description:Combination antitumor treatments are essential parts of modern tumor therapy as-compared to monotherapies-(i) they are more effective; (ii) the dose of the compounds can be reduced; and (iii) therefore the side effects are improved. Our research group previously demonstrated the antitumor character of bortezomib (BOZ) in A2058 melanoma cells. Unfortunately, dose-related side effects are common during BOZ therapy, which could be prevented by reducing the dose of BOZ. This study aimed to characterize synergistic combinations of BOZ with a TRAIL (TNF-related apoptosis-inducing ligand) -inducing compound (TIC10), where the doses can be cut down but the efficacy is preserved. Endpoint cell viability assays were performed on A2058 cells, and synergism of BOZ and TIC10 was observed after 72 h. Synergism was further validated in a real-time impedimetric assay, and our results showed that BOZ-treated melanoma cells survived the treatment, an effect not registered in the co-treatments. Treatment with the combinations resulted in increased apoptosis, which was not accompanied by enhanced LDH release. Nevertheless, the expression of death receptor 5 (DR5) was increased on the cell surface without transcriptional regulation. In summary, our findings support the theory that the application of BOZ and TIC10 in combination could provide higher efficacy in vitro.

| S-EPMC8399995 | biostudies-literature

TGF?1 treatment of A2058 melanoma cells

Project description:4 replicates were prepared from A2058 melanoma cells [transfected with 10ng of empty vector (pcDNA3.1+)] and treated with 5ng/ml TGFβ1 or vehicle control for 24hrs This is the control arm of a larger experiment where cells transfected with a particular expression plasmid were treated with TGFβ1 or control vehicle. The transfection with the expresion plasmid was unsucessful so this empty vector data has been used alone to simply examine the effect of TGFβ1 treatment on A2058 cells.

| S-ECPF-GEOD-66114 | biostudies-other

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data